

**REMARKS**

The Examiner has required restriction of the claimed invention, and listed the following group classifications:


<b>Group Claim(s)</b>	<b>Description</b>
I      1-5, 7, 18-23, 27, 32-35	methods comprising PCR
II     6-35	methods comprising cell lines
III    36-39	antibodies
IV    40	compositions comprising cells and a protease inhibitor
V    41-47	methods comprising cells and a protease inhibitor

In addition, the Examiner has subjected Group V to further species restrictions: a, influenza virus detection; b, parainfluenza virus detection; c, adenovirus detection; d, respiratory syncytial virus detection; and e, metapneumovirus detection.

Applicants hereby elect to prosecute the method claims of Group I, without traverse. Nonetheless, Applicants have amended Claims 6, 8, 9, 24, 28, 29, and 31, and canceled Claims 7 and 27, in order to further the prosecution of the present application and Applicants' business interests, yet without acquiescing to the Examiner's arguments. Applicants reserve the right to prosecute the original, similar, or broader claims in one or more future application(s). These amendments do not introduce new matter, and are not intended to narrow the scope of any of the claims within the meaning of *Festo*.<sup>1</sup>

Dated: June 29, 2005

By: \_\_\_\_\_

  
Christine A. Lekutis

Registration No. 51,934

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
415.904.6500

---

<sup>1</sup> *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 535 U.S. 722, 122 S.Ct. 1831, 1838, 62 USPQ2d 1705, 1710 (2002).